CDK4 and neoplasm: Interestingly, a combination of OTX015 and abemaciclib (the most potent of the 3 clinically approved CDK4/6 inhibitors) exhibited remarkable efficacy and superior tumor regression compared with the current standard-of-care treatment of abemaciclib + fulvestrant.